Central Nervous System Therapeutics Market Size (2024 - 2029)

The market size of Global Central Nervous System Therapeutics is expected to grow significantly in the upcoming years. This growth is influenced by various factors including the COVID-19 pandemic, which has led to increased mental health issues worldwide, thus impacting the market. The rise in the prevalence of Central Nervous System (CNS) diseases such as mental health and neurodegenerative diseases is also expected to drive the market's growth due to the increased usage of CNS therapeutics. The development of novel drug delivery systems for neurological drugs is another contributing factor expected to propel market growth. Despite the high research and development expenditure and potential adverse reactions associated with CNS therapeutics, the high burden of CNS diseases, increasing demand for CNS therapeutics, and novel drug delivery systems are likely to boost the market size over the forecast period.

Market Size of Central Nervous System Therapeutics Industry

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:
Central Nervous System Therapeutics Market Summary
Study Period 2019 - 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
CAGR 6.02 %
Fastest Growing Market Asia Pacific
Largest Market North America

Major Players

Central Nervous System Therapeutics Market Major Players

*Disclaimer: Major Players sorted in no particular order

setting-icon

Need a report that reflects how COVID-19 has impacted this market and its growth?

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Central Nervous System Therapeutics Market Analysis

The Global Central Nervous System Therapeutics Market size is expected to grow from USD 112,884.87 million in 2023 to USD 151,208.00 million by 2028, at a CAGR of 6.02% during the forecast period.

COVID-19 cases worldwide profoundly impacted the CNS therapeutics market as lockdown restrictions created few mental disturbances in people. For instance, according to a research brief published by the WHO in March 2022, anxiety and sadness surged dramatically worldwide by 25% in the first year of the COVID-19 pandemic. The increase in the prevalence of mental health problems coincided with severe disruptions to mental health services, leaving huge gaps in care and adversely impacting the studied market during the pandemic. Further, as per the source mentioned above, by the end of 2021, things will have somewhat improved, but still, far too many people are unable to get the care and support they need for both current and newly developed mental health illnesses, thereby adversely impacting the market over the post-pandemic period.

An increase in the number of patients suffering from central nervous system (CNS) diseases such as mental health and neurodegenerative diseases and other CNS diseases increases the usage of CNS therapeutics which is expected to drive the market's growth. For instance, according to the March 2023 World Health Organization (WHO) report, more than 55 million people have dementia worldwide, and nearly 10 million new cases are reported yearly. As per the same source, Alzheimer's is the most common form of dementia and constitutes about 60-70% of the total cases of dementia. Similarly, as per the report published by Ridgecrest Regional Hospital in May 2022, one billion people globally, or 12% of the world's population, suffer from migraines. In addition, there is a massive demand for CNS therapeutics, and government and non-government entities are raising funds to support the authorization of CNS therapeutics, which is expected to fuel the growth in the market. For instance, in May 2022, Minoryx raised USD 55.4 USD million (EUR 51 million) to support marketing authorization applications and launch preparations for X-linked Adrenoleukodystrophy (X-ALD) therapy for orphan central nervous system (CNS) disorders. Hence, the high prevalence of CNS diseases likely increases the demand for therapeutics and new developments, which are expected to boost growth in the studied market.

The development of novel drug delivery systems is expected to increase the usage of various neurological drugs through these systems, which will likely propel the market to grow. For instance, in January 2023, Spark Therapeutics and Neurochase entered a strategic collaboration to develop Neurochase's proprietary delivery technology for use with selected gene therapies for rare diseases in CNS. Through this collaboration, Neurochase will bring its deep direct drug delivery technology expertise to Spark's leading AAV platform, which is expected to grow significantly in the studied market over the forecast period.

Therefore, the high burden of CNS diseases, increasing demand for CNS therapeutics, and the development of novel drug delivery systems likely increase the need for the market products and are expected to boost the market over the forecast period. However, high research and development expenditure in developing CNS therapeutics and adverse reactions associated with them are expected to restrain the growth of the studied market over the forecast period.

Central Nervous System Therapeutics Industry Segmentation

As per the scope, the central nervous system (CNS) consists of the brain and spinal cord. It controls things like thought, movement, and emotion, as well as breathing, heart rate, hormones, and body temperature. The drugs that act on the functions of the brain and spinal cord are central nervous system therapeutics. The central nervous system therapeutics market is segmented by Disease (Neurovascular Diseases, Trauma, Mental Health, Degenerative Disease, Infectious Diseases, Cancer, and Others), Drug Class (Analgesics, Antidepressants, Anesthetics, Anti-Parkinson Drugs, Anti-Epileptics, and Other Drug Classes), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD million) for the above segments.

By Disease
Neurovascular Diseases
Trauma
Mental Health
Anxiety Disorders
Epilepsy
Psychotic Disorders
Other Mental Health Disorders
Degenerative Diseases
Alzheimer's Disease
Parkinson's Disease
Multiple Sclerosis
Amyotrophic Lateral Sclerosis
Other Degenerative Diseases
Infectious Diseases
Cancer
Other Diseases
By Drug Class
Analgesics
Antidepressant
Anesthetics
Anti-Parkinson Drugs
Anti-Epileptics
Other Drug Classes
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America

Central Nervous System Therapeutics Market Size Summary

The global Central Nervous System (CNS) Therapeutics Market is set to experience significant growth over the forecast period. This expansion is primarily due to the rising prevalence of CNS diseases such as mental health and neurodegenerative conditions. The COVID-19 pandemic has also had a substantial impact on the market, with lockdown restrictions leading to an increase in mental health issues worldwide. Despite some improvements, many individuals still lack access to necessary care and support for mental health illnesses, which continues to affect the market. Furthermore, the development of novel drug delivery systems is expected to increase the usage of various neurological drugs, further driving market growth. The CNS Therapeutics Market is highly competitive, with several key players. The increasing demand for CNS therapeutics and the high burden of CNS diseases are likely to boost the need for market products. However, the high cost of research and development for CNS therapeutics and associated adverse reactions may hinder market growth. The Parkinson's Disease segment under the Degenerative Disease category is expected to hold a major market share due to the rising prevalence of the condition and increased research and development of new therapeutics. North America is anticipated to have a significant market share due to advancements in technology, product launches, and a high incidence of CNS diseases.

Explore More

Central Nervous System Therapeutics Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Rise in Burden of CNS Disorders

      2. 1.2.2 Increase in Generic Drugs

      3. 1.2.3 Development of Novel Drug Delivery Systems

    3. 1.3 Market Restraints

      1. 1.3.1 Adverse Events Associated with CNS Therapeutics

      2. 1.3.2 High R&D Costs

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Bargaining Power of Buyers/Consumers

      2. 1.4.2 Bargaining Power of Suppliers

      3. 1.4.3 Threat of New Entrants

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size by Value - in USD Million)

    1. 2.1 By Disease

      1. 2.1.1 Neurovascular Diseases

      2. 2.1.2 Trauma

      3. 2.1.3 Mental Health

        1. 2.1.3.1 Anxiety Disorders

        2. 2.1.3.2 Epilepsy

        3. 2.1.3.3 Psychotic Disorders

        4. 2.1.3.4 Other Mental Health Disorders

      4. 2.1.4 Degenerative Diseases

        1. 2.1.4.1 Alzheimer's Disease

        2. 2.1.4.2 Parkinson's Disease

        3. 2.1.4.3 Multiple Sclerosis

        4. 2.1.4.4 Amyotrophic Lateral Sclerosis

        5. 2.1.4.5 Other Degenerative Diseases

      5. 2.1.5 Infectious Diseases

      6. 2.1.6 Cancer

      7. 2.1.7 Other Diseases

    2. 2.2 By Drug Class

      1. 2.2.1 Analgesics

      2. 2.2.2 Antidepressant

      3. 2.2.3 Anesthetics

      4. 2.2.4 Anti-Parkinson Drugs

      5. 2.2.5 Anti-Epileptics

      6. 2.2.6 Other Drug Classes

    3. 2.3 Geography

      1. 2.3.1 North America

        1. 2.3.1.1 United States

        2. 2.3.1.2 Canada

        3. 2.3.1.3 Mexico

      2. 2.3.2 Europe

        1. 2.3.2.1 Germany

        2. 2.3.2.2 United Kingdom

        3. 2.3.2.3 France

        4. 2.3.2.4 Italy

        5. 2.3.2.5 Spain

        6. 2.3.2.6 Rest of Europe

      3. 2.3.3 Asia-Pacific

        1. 2.3.3.1 China

        2. 2.3.3.2 Japan

        3. 2.3.3.3 India

        4. 2.3.3.4 Australia

        5. 2.3.3.5 South Korea

        6. 2.3.3.6 Rest of Asia-Pacific

      4. 2.3.4 Middle East and Africa

        1. 2.3.4.1 GCC

        2. 2.3.4.2 South Africa

        3. 2.3.4.3 Rest of Middle East and Africa

      5. 2.3.5 South America

        1. 2.3.5.1 Brazil

        2. 2.3.5.2 Argentina

        3. 2.3.5.3 Rest of South America

Central Nervous System Therapeutics Market Size FAQs

The Global Central Nervous System Therapeutics Market is projected to register a CAGR of 6.02% during the forecast period (2024-2029)

Biogen, Novartis AG, Merck KGaA, Eli Lilly and Company and Johnson & Johnson are the major companies operating in the Global Central Nervous System Therapeutics Market.

Central Nervous System Therapeutics Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)